Population-level effect of HSV-2 therapy on the incidence of HIV in sub-Saharan Africa

Sexually Transmitted Infections

Volumn 84, Issue SUPPL. 2, 2008, Pages

  White, R G ^a   Freeman, E E ^a   Orroth, K K ^a   Bakker, R ^b   Weiss, H A ^a   O'Farrell, N ^c   Buve A ^d   Hayes, R J ^a   Glynn, J R ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c EALING HOSPITAL   (United Kingdom)

^d INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AFRICA; AGE DISTRIBUTION; ARTICLE; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; PRIORITY JOURNAL; SEX DIFFERENCE;

ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; AGE DISTRIBUTION; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; MALE; PREVALENCE;

EID: 53649108560     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.2008.029918     Document Type: Article

References (50)

1. Mbopi-Keou FX, Gresenguet G, Mayaud P, et al. Genital herpes simplex virus type 2 shedding is increased in HIV-infected women in Africa. AIDS 1999;13:536-7.
2. Mbopi-Keou FX, Gresenguet G, Mayaud P, et al. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J Infect Dis 2000;182:1090-6.
3. Schacker T, Zeh J, Hu HL, et al. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis 1998;178:1616- 22.
4. Corey L, Wald A, Celum CL, et al. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004;35:435-45.
5. McFarland W, Gwanzura L, Bassett MT, et al. Prevalence and incidence of herpes simplex virus type 2 infection among male Zimbabwean factory workers. J Infect Dis 1999;180:1459-65.
6. Schacker T, Zeh J, Hu H, et al. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 2002;186:1718-25.
7. Serwadda D, Gray RH, Sewankambo NK, et al. Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda. J Infect Dis 2003;188:1492-7.
8. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001;357:1149-53.
9. Schacker T, Ryncarz AJ, Goddard J, et al. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998;280:61-6.
10. Mbopi-Keou FX, Legoff J, Gresenguet G, et al. Genital shedding of herpes simplex virus-2 DNA and HIV-1 RNA and proviral DNA in HIV-1- and herpes simplex virus-2-coinfected African women. J Acquir Immune Defic Syndr 2003;33:121-4.
11. McClelland RS, Wang CC. Overbaugh J, et al. Association between cervical shedding of herpes simplex virus and HIV-1. AIDS 2002;16:2425-30.
12. Kilmarx PH, Limpakarnjanarat K, Mastro TD, et al. HIV-1 seroconversion in a prospective study of female sex workers in northern Thailand: continued high incidence among brothel-based women. AIDS 1998;12:1889-98.
13. Celum C, Levine R, Weaver M, et al. Genital herpes and human immunodeficiency virus: double trouble. Bull World Health Organ 2004;82:447-53.
14. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002;185:45-52.
15. Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006;20:73-83.
16. Cowan FF, Pascoe SJ, Barlow KL, et al. Association of genital shedding of herpes simplex virus type 2 and HIV-1 among sex workers in rural Zimbabwe. AIDS 2006;20:261-7.
17. LeGoff J, Weiss HA, Gresenguet G, et al. Cervicovaginal HIV-1 and herpes simplex virus type 2 shedding during genital ulcer disease episodes. AIDS 2007;21:1569-78.
18. Celum CL, Robinson NJ, Cohen MS. Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection. J Infect Dis 2005;191(Suppl 1):S107-14.
19. Mayaud P. Impact of HSV-2 episodic therapy on HIV-1 and HSV-2 genital shedding, and ulcer healing among women in Ghana and Central African Republic: randomised controlled trial (ANRS 1212). International AIDS Conference; Toronto, 2006.
20. Paz Bailey G, Sternberg M, Puren A, et al. Impact of episodic acyclovir therapy on genital ulcer duration and HIV shedding from herpetic ulcers among men in South Africa. ISSTDR; Seattle, 2007.
21. Zuckerman RA, Lucchetti A, Whittington WL, et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/ HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis 2007;196:1500-8.
22. Delany S, Mayaud P, Clayton T, et al. Impact of HSV-2 suppressive therapy on genital and plasma HIV-1 RNA in HIV-1 and HSV-2-seropositive women not taking ART: a randomized, placebo-controlled trial in Johannesburg, South Africa. CROI, 2007.
23. Dunne E, Whitehead S, Whitehead S, et al. The effect of suppressive acyclovir therapy on HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand. CROI, 2007.
24. Nagot N, Ouedraogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007;356:790-9.
25. Tanton C, Watson-Jones D, Rusizoka M, et al. A randomized controlled trial in Tanzania to assess the impact of HSV-2 suppressive therapy on genital HIV viral load among HSV-2 and HIV-1 seropositive women. ISSTDR; Seattle, 2007.
26. Baeten JM, Strick LB, Lucchetti A, et al. Herpes simplex virus suppressive treatment decreases plasma HIV-1 viral load in HSV-2/HIV-1 co-infected women: a randomized, placebo-controlled, cross-over trial. ISSTDR; Seattle, 2007.
27. Perry CM, Faulds D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 1996;52:754-72.
28. Watson-Jones DL, Rusizoka M, Weiss H, et al. A randomised controlled trial to determine the impact of HSV -2 suppressive therapy on HIV incidence in HSV-2 seropositive women in Tanzania. ISSTDR; Seattle, 2007.
29. Celum C, Wald J, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008;371 :2109-19.
30. Blower S, Ma L. Calculating the contribution of herpes simplex virus type 2 epidemics to increasing HIV incidence: treatment implications. Clin Infect Dis 2004;39(Suppl 5):S240-7.
31. Korenromp EL, Bakker R, De Vlas SJ, et al. Can behavior change explain increases in the proportion of genital ulcers attributable to herpes in sub-Saharan Africa? A simulation modeling study. Sex Transm Dis 2002;29:228-38.
32. Korenromp EL, Bakker R, Gray R, et al. The effect of HIV, behavioural change, and STD syndromic management on STD epidemiology in sub-Saharan Africa: simulations of Uganda. Sex Transm Infect 2002;78(Suppl 1):i55-63.
33. Freeman E, Orroth K, White RG, et al. The proportion of new HIV infections attributable to HSV-2 increases over time: simulations of the changing role of sexually transmitted infections in sub-Saharan African HIV epidemics. Sex Trans Infect 2007;83(Suppl 1):i17-24.
34. Orroth KK, Freeman E, Bakker R, et al. Understanding differences across the contrasting epidemics in East and West Africa: results from a simulation model of the Four Cities Study. Sex Transm Infect 2007;83(Suppl 1):15-16.
35. Buve A, Carael M, Hayes RJ, et al. Multicentre study on factors determining differences in rate of spread of HIV in sub-Saharan Africa: methods and prevalence of HIV infection. AIDS 2001;15(Suppl 4):S5-14.
36. Orroth K. Investigations of the proportion of HIV infections attributable to sexually transmitted diseases in Sub-Saharan Africa based on data from the Mwanza and Rakai trials. London: London School of Hygiene and Tropical Medicine, 2003.
37. Korenromp E, van Vliet C, Bakker R, et al. HIV spread and partnership reduction for different patterns of sexual behaviour: a study with the microsimulation model STDSIM. Math Popul Studies 2000;8:135- 73.
38. van Vliet C, Holmes KK, Singer B, et al. The effectiveness of HIV prevention strategies under alternative scenarios: evaluation with the STDSIM model. In: Bank W, ed. Confronting AIDS: Public priorities in a global epidemic A World Bank Policy Research Report. Oxford: Oxford University Press, 1997:207-37.
39. Korenromp EL Van Vliet C, Grosskurth H, et al. Model-based evaluation of single-round mass treatment of sexually transmitted diseases for HIV control in a rural African population. AIDS 2000;14:573-93.
40. Schmidt WP, Schim VLM, Aaby P, et al. Behaviour change and competitive exclusion can explain the diverging HIV-1 and HIV-2 prevalence trends in Guinea-Bissau. Epidemiol Infect 2008;136:551-61.
41. White RG, Orroth KK, Korenromp EL et al. Can population differences explain the contrasting results of the Mwanza, Rakai, and Masaka HIV/sexually transmitted disease intervention trials?: a modeling study. J Acquir Immune Defic Syndr 2004;37:1500-13.
42. Korenromp EL White RG, Orroth KK, et al. Determinants of the impact of sexually transmitted infection treatment on prevention of HIV infection: a synthesis of evidence from the Mwanza, Rakai, and Masaka intervention trials. J Infect Dis 2005;191(Suppl 1):S168-78.
43. Orroth KK, White RG, Korenromp EL, et al. Empirical observations underestimate the proportion of human immunodeficiency virus infections attributable to sexually transmitted diseases in the Mwanza and Rakai sexually transmitted disease treatment trials: simulation results. Sex Transm Dis 2006;33:536-44.
44. White RG, Orroth KK, Glynn JR. et al. Treating curable sexually transmitted infections to prevent HIV in Africa: still an effective control strategy? J Acquir Immune Defic Syndr 2008,47:346-53.
45. White RG, Glynn J, Orroth KK, et al. Male circumcision for HIV prevention in sub-saharan Africa: who, what and when? AIDS 2008;22(in press).
46. Buve A, Lagarde E, Carael M, et al. Interpreting sexual behaviour data: validity issues in the multicentre study on factors determining the differential spread of HIV in four African cities. AIDS 2001;15(Suppl 4):S117-26.
47. Weiss H,Buvé A,Robinson N,et al.The epidemiologyof HSV-2 infection and its association with HIV infection in four urban African populations. AIDS 2001;15(Suppl 4):S97-108.
48. langenberg A, Benedetti J, Jenkins J, et al. Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" herpes simplex virus type 2 infection. Ann Intern Med 1989;110:882-7.
49. World Health Organization Guidelines for the management of sexually transmitted infections. Geneva: World Health Organization, 2003.
50. Obasi A, Mosha F, Quigley M, et al. Antibody to HSV-2 as a marker of sexual risk behaviour in rural Tanzania. J Infect Dis 1999;179:16-24.